Objective This study aimed to identify potential susceptibility loci for testicular germ cell tumors (TGCT) through a comprehensive multi-omics analysis. Methods A Mendelian randomization (MR) analysis was conducted to investigate the causal relationships between immune cell phenotypes and TGCT. Summary-based Mendelian Randomization (SMR) and colocalization analyses were subsequently performed to examine candidate phenotypes and TGCT using quantitative trait locis from multiple datasets. Differential gene expression analysis was employed to explore the immune landscape of the target gene in the TGCT tumor microenvironment using UCSC databases. Additionally, potential pathway mechanisms were investigated to elucidate the functional role of candidate genes. Results MR analysis identified a significant causal association between the immune cell phenotype HLA-DR on monocytes and TGCT (p = 0.02). SMR analysis revealed that BDH2 was significantly associated with TGCT susceptibility (OR = 0.597, p = 2.21e-07). Colocalization analysis suggested shared genetic variation between BDH2 and TGCT (PP.H4 = 0.95). Immunohistochemistry staining confirmed that BDH2 mRNA levels were significantly lower in TGCT tissues than in normal controls (p < 0.001). In the TGCT tumor microenvironment, lower BDH2 expression was associated with higher immune scores, with T cells and B cells predominantly enriched in the low-expression group, whereas monocytes and endothelial cells were more abundant in the high-expression group. Furthermore, members of the HLA family, exhibited significant correlations between their methylation levels and low BDH2 expression groups. Pathway analysis indicated that BDH2 may influence TGCT progression through the RAS-MAPK signaling pathway. Conclusions Our findings support a significant susceptibility relationship between the phenotype HLA-DR on monocytes, BDH2, and TGCT.
Objective To investigate the potential causal relationship between height and the risk of developing testicular cancer using Mendelian Randomization analysis. Methods We utilized phenotype data on height and testicular cancer from two European ancestry cohorts, integrating data from the IEU, FinnGen, and UK Biobank databases. Linkage Disequilibrium Score regression and SNP-associated gene enrichment analyses were initially conducted to assess the association between SNPs and the phenotypes. A two-sample MR approach was then applied to evaluate the causal relationship between height and testicular cancer risk. An additional cohort was analyzed for validation, followed by a meta-analysis to combine results. Reverse MR and colocalization analyses were performed to investigate potential reverse causality. Gene enrichment analysis was conducted to elucidate the biological mechanisms linking height to testicular cancer, and potential eQTL targets for testicular cancer were explored using summary-data-based MR and colocalization analysis. Results The Inverse Variance Weighted method revealed a significant association between genetically predicted height and testicular cancer risk, with an odds ratio of 1.372 (95% CI: 1.024-1.837, p-value < 0.05). Gene enrichment analysis suggested that the extracellular matrix-related pathway might underlie the increased risk of testicular cancer associated with height. PMF1 and SLC9B2 were identified as potential targets for testicular cancer from summary-data-based MR, colocalization, and gene expression analysis. Conclusions This Mendelian randomization study provides evidence supporting a causal relationship between height and the risk of developing testicular cancer, with PMF1 and SLC9B2 identified as potential targets for further investigation.